PROSES Study Evaluating Impact of Sarecycline

PROSES Study Evaluating Impact of Sarecycline

Recent research highlights the importance of patient-reported outcomes (PROs) in assessing the impact of acne vulgaris (AV) alongside clinician evaluations. A prospective cohort study involved 253 patients, aged 9 and older, with moderate to severe non-nodular AV who received sarecycline treatment over 12 weeks. Key findings showed significant reductions in symptoms measured by the Acne Symptom and Impact Scale (ASIS), with notable improvements in physical signs, emotional distress, and social impact. The Investigator’s Global Assessment indicated a 58.9% success rate in severity reduction, while 88.1% of physicians were satisfied with treatment outcomes. Although 10.3% of patients reported adverse events, the overall results demonstrate that sarecycline significantly alleviates both symptoms and the psychosocial burden of AV.

Click here for a link to the original article.

Elevate-Derm Alliance Editorial Committee